Last reviewed · How we verify
BAY14-2222_Kogenate-FS FVIII
BAY14-2222_Kogenate-FS FVIII is a Factor VIII replacement therapy Biologic drug developed by Bayer. It is currently in Phase 2 development for Hemophilia A.
Factor VIII replacement therapy
Factor VIII replacement therapy Used for Hemophilia A.
At a glance
| Generic name | BAY14-2222_Kogenate-FS FVIII |
|---|---|
| Sponsor | Bayer |
| Drug class | Factor VIII replacement therapy |
| Target | Factor VIII |
| Modality | Biologic |
| Therapeutic area | Hematology |
| Phase | Phase 2 |
Mechanism of action
BAY14-2222_Kogenate-FS FVIII is a recombinant human coagulation factor VIII used to treat hemophilia A.
Approved indications
- Hemophilia A
Common side effects
- Headache
- Nausea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAY14-2222_Kogenate-FS FVIII CI brief — competitive landscape report
- BAY14-2222_Kogenate-FS FVIII updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about BAY14-2222_Kogenate-FS FVIII
What is BAY14-2222_Kogenate-FS FVIII?
BAY14-2222_Kogenate-FS FVIII is a Factor VIII replacement therapy drug developed by Bayer, indicated for Hemophilia A.
How does BAY14-2222_Kogenate-FS FVIII work?
Factor VIII replacement therapy
What is BAY14-2222_Kogenate-FS FVIII used for?
BAY14-2222_Kogenate-FS FVIII is indicated for Hemophilia A.
Who makes BAY14-2222_Kogenate-FS FVIII?
BAY14-2222_Kogenate-FS FVIII is developed by Bayer (see full Bayer pipeline at /company/bayer).
What drug class is BAY14-2222_Kogenate-FS FVIII in?
BAY14-2222_Kogenate-FS FVIII belongs to the Factor VIII replacement therapy class. See all Factor VIII replacement therapy drugs at /class/factor-viii-replacement-therapy.
What development phase is BAY14-2222_Kogenate-FS FVIII in?
BAY14-2222_Kogenate-FS FVIII is in Phase 2.
What are the side effects of BAY14-2222_Kogenate-FS FVIII?
Common side effects of BAY14-2222_Kogenate-FS FVIII include Headache, Nausea, Fatigue.
What does BAY14-2222_Kogenate-FS FVIII target?
BAY14-2222_Kogenate-FS FVIII targets Factor VIII and is a Factor VIII replacement therapy.
Related
- Drug class: All Factor VIII replacement therapy drugs
- Target: All drugs targeting Factor VIII
- Manufacturer: Bayer — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Hemophilia A
- Compare: BAY14-2222_Kogenate-FS FVIII vs similar drugs
- Pricing: BAY14-2222_Kogenate-FS FVIII cost, discount & access